

Platelets Activation and Liver Transplantation

Masanobu Usui¹, Hideo Wada^{2*}, Shugo Mizuno¹ and Shuji Isaji¹

¹Hepatobiliary Pancreatic and Transplant Surgery, Mie University Graduate School of Medicine, Mie, Japan

²Department of Molecular and Laboratory Medicine, Mie University Graduate School of Medicine, Mie, Japan

*Corresponding author: Hideo Wada, Department of Molecular and Laboratory Medicine, Mie University, Graduate School of Medicine, 2-174 Edobashi, Tsu, Mie 514-8507, Japan, Tel: 81-59-232-1111; E-mail: wadahide@clin.medic.mie-u.ac.jp

Received date: October 5, 2015; Accepted date: April 20, 2017; Published date: April 22, 2017

Copyright: © 2017 Usui M, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Transient thrombocytopenia is a common phenomenon after living donor liver transplantation (LDLT), and severe thrombocytopenia after LDLT is associated with graft loss and poor patient outcomes. The various causes of thrombocytopenia include bone marrow hematopoiesis failure due to decreased thrombopoietin (TPO) production in the injured liver, platelet destruction associated with splenomegaly, and the activation and consumption of platelets due to various forms of thrombosis, including disseminated intravascular coagulation (DIC), thrombotic microangiopathy (TMA), and venous thromboembolism (VTE).

The observation of biomarkers such as soluble platelet glycoprotein VI (sGPVI), TPO, von Willebrand factor (VWF), VWF propeptide (VWFpp), and disintegrin-like and metalloproteinase with thrombospondin type-1 motifs member 13 (ADAMTS13) is useful in the evaluation of the mechanisms of thrombocytopenia in patients who undergo LDLT. The presence of these biomarkers, including sGPVI, ADAMTS13, VWF and VWFpp, suggests that platelet activation occurs in the early phase of LDLT and that vascular endothelial cell injury occurs on post-operative days 7-14.

Keywords: sGPVI; Living donor liver transplantation; Thrombocytopenia; Mortality; ADAMTS13

Introduction

Living donor liver transplantation (LDLT) was first performed in Japan in 1989 [1]. Unique technical, physiological, and logistical innovations in LDLT [2,3] have since developed. Over the last two decades, LDLT operations have been markedly improved by innovations that now achieve results comparable to those obtained with deceased donor liver transplantation (DDLT). Technical improvements in living donor surgery have led to the generalization of pediatric LDLT with excellent patient and graft survival outcomes [4]. There is no evidence to support a higher incidence of hepatocellular carcinoma (HCC) recurrence after LDLT than after DDLT [5].

However, room for further innovation remains, particularly with adult LDLT. The 5-year graft survival rate is less than 70% when ABO-incompatible LDLT is performed in children [2,6], and specific diseases and preoperative patient conditions are associated with different transplantation outcomes [3,7,8]. In the registry of the Japanese Liver Transplantation Society from November 1989 to December 2010, the 1-, 5-, 10-, and 20-year patient survival rates were 88.3%, 85.4%, 82.8%, and 79.6%, respectively [9]. The 1-, 5-, and 10-year overall survival and disease-free survival rates after LDLT for patients with combined hepatocellular-cholangiocarcinoma were 87.5%, 72.9%, and 48.6% and 85.7%, 85.7%, and 85.7%, respectively [10]. Nationwide surveys of acute liver failure (ALF) are conducted annually in Japan, and 20% of patients with ALF undergo liver transplantation (LT) [11]. In LDLT for patients with ALF, the cumulative patient survival rate at 1 year after LT was 79% [11]. The causes of a poor outcomes after LDLT are said to include graft dysfunction and various complications such as infection, thrombosis,

bleeding, graft-versus-host disease [12], thrombotic microangiopathy (TMA) [13,14], and disseminated intravascular coagulation (DIC) (Table 1) [15].

Causes	
Hypoproduction of platelets in the bone marrow	Low TPO due to liver injury or bone marrow suppression
Increased destruction in the spleen	Splenomegaly, portal vein hypertension
Consumption of platelets due to thrombosis	DIC, TMA, HIT, VTE
Consumption of platelets without thrombosis	Infections, multiple organ failure

TPO-Thrombopoietin; DIC- Disseminated intravascular coagulation; TMA-Thrombotic microangiopathy; HIT-Heparin induced thrombocytopenia; VTE-Thromboembolism.

Table 1: The causes of thrombocytopenia in LDLT.

Role of Platelets

Platelets, which are anuclear blood cells, are derived from megakaryocytes, which play important roles in hemostasis. Platelets contain not only the proteins needed for hemostasis such as serotonin, adenosine 5'-diphosphate, adenosine 5'-triphosphate, and sphingosine 1-phosphate, but also many growth factors such as hepatocyte growth factor, insulin-like growth factor, vascular endothelial growth factor, epidermal growth factor, platelet-derived growth factor, and transforming growth factor- β , which are required for tissue regeneration or repair [16-18]. Platelets play a crucial role in

promoting liver regeneration [19,20] as well as both preventive and promoting effects on the progression of liver fibrosis and both protective and harmful effects concerning acute liver injury *in vitro* and *in vivo*. In the clinical setting, the increase in the number of platelets induced by platelet transfusion improves the liver function in patients with chronic liver diseases and cirrhosis [18]. In addition, it has been reported that splenectomy, which increases the platelet count, contributes to the improvement of the liver function [20]. However, increased platelets have been conversely reported to exert harmful effects on liver fibrosis and acute liver injury including thrombosis, viral hepatitis, and ischemia-reperfusion [18,21].

Thrombocytopenia and Patient Outcomes

Transient thrombocytopenia is a common phenomenon after LT, and the recovery of platelet counts is clinically significant. In 1992, McCaughan et al. [11] were the first to report that thrombocytopenia on post-operative day (POD) 14 after LT was associated with the patient survival: the platelet counts in non-survivors were significantly lower than those in survivors (88×10^3 vs. $174 \times 10^3/\mu\text{l}$; $p < 0.01$). Furthermore, they reported that graft liver dysfunction was the most useful independent predictor of a nadir of platelet counts after LT, although various mechanisms of thrombocytopenia were proposed. Following this report, two additional studies [22,23] confirmed that severe thrombocytopenia after LT was associated with graft loss or a poor patient outcome. However, the precise mechanisms by which post-transplant thrombocytopenia occurs and its relationship with graft dysfunction remain unclear. The mechanisms contributing to graft dysfunction are multifactorial and include small-for-size graft [5], old age [24], ischemic reperfusion injury, sinusoidal endothelial cells injury, platelet aggregation, immunological reactions, and inflammatory responses [25,26]. The platelet counts in patients with successful LT usually increase by POD14.

Although the patients in our study gradually recovered from early thrombocytopenia after LDLT within 14 days, there were several patients who showed a delayed recovery of their platelet count, exhibiting prolonged thrombocytopenia [27]. Adult LDLT patients were divided into 2 groups based on their platelet counts ($100 \times 10^3/\mu\text{l}$) on POD14: high- and low-platelet (HP and LP, respectively) groups. The 6-month survival rate in the LP group was significantly lower than that in the HP group (61.1% vs. 93.5%) [27], suggesting that a platelet count of $<100 \times 10^3/\mu\text{l}$ on POD14 is a strong predictor of the patient survival after LDLT (Figure 1).

It was recently reported in DDLT that a low platelet count on POD-5 was associated with graft loss and mortality after LT, thus suggesting that thrombocytopenia can be a poor prognostic marker [28].

Splenectomy and Thrombocytopenia

Splenectomy increases the platelet count almost without exception, as it removes the major site of platelet destruction and reduces antibody production, resulting in prolonged platelet survival times [29]. Post-splenectomy transient thrombocytosis occurs and unusually reaches a peak on POD14. However, it has been reported that the peak platelet count following splenectomy after LDLT occurs on POD28 [30-32]. Although splenectomy is not usually performed for DDLT patients, several transplant centers performing LDLT have introduced simultaneous splenectomy to control portal pressure in small-for-size graft recipients, preventing thrombocytopenia in HCV-positive

recipients for whom postoperative direct antiviral agents instead of interferon treatment is planned, and for patients undergoing ABO-incompatible LDLT [30-32]. Marubashi et al. [31] found that seven patients who underwent simultaneous splenectomy showed a remarkable increase in their platelet counts after LDLT on POD14, with the peak in the platelet count seen at POD28. We encountered several LDLT patients who had suffered from prolonged thrombocytopenia even after splenectomy [27]. Our study also showed that the platelet counts after splenectomy in operations other than LDLT significantly increased on POD7 and peaked on POD14. In LDLT, however, the platelet counts remained low until POD7 and significantly increased on POD14 but did not peak on POD14, even after splenectomy.




Figure 1: The behavior of biomarkers during LDLT. Closed symbols, low platelet group ($<100 \times 10^3/\mu\text{l}$); open symbols, high platelet group ($\geq 100 \times 10^3/\mu\text{l}$); VWFpp, von Willebrand factor propeptide; ADAMTS13, disintegrin-like and metalloproteinase with thrombospondin type-1 motifs member 13; PLT, platelet number.

Biomarkers of Thrombocytopenia

Soluble platelet glycoprotein VI (sGPVI)

sGPVI is a type I transmembrane glycoprotein of the immunoreceptor family that is constitutively associated and expressed with the Fc receptor γ -chain, an immunoreceptor tyrosine-based activation motif-bearing receptor [33]. Upon platelet activation, the platelet surface GPVI is cleaved by proteases, such as ADAM10, releasing sGPVI [34,35]. sGPVI has recently received attention as a platelet activation marker, as described below. Several groups have reported that sGPVI is a useful biomarker of diseases caused by platelet activation, such as acute coronary syndrome and stroke [36,37]. The plasma sGPVI levels have been reported to be significantly increased in patients with thrombosis during the postoperative period [38] and in patients with DIC or TMA [39], suggesting that the plasma sGPVI levels increase in a thrombotic state, which activates platelets (Tables 2 and 3).

	Production from	Diagnosis	Poor outcome	POD
TPO	Hepatocytes	Thrombopoiesis	Low	28 days
sGPVI	Platelets	Platelet activation	Elevation	Three days
ADAMTS13	Stellate cells	Platelet activation by ULM-VWF	Markedly low	One day
VWFpp	Vascular endothelial cells	Vascular endothelial cell injuries	Markedly high	7-14 days
VWF	Vascular endothelial cells	Vascular endothelial cell injuries	Markedly high	7-14 days

TPO-Thrombopoietin; sGPVI- Soluble platelet glycoprotein VI; VWF-Von Willebrand factor; VWFpp- VWF propeptide; ADAMTS13-Disintegrin-like and metalloproteinase with thrombospondin type-1 motifs member 13; UL-VWFM-Unusual large VWF multimers.

Table 2: The biomarkers for thrombocytopenia in LDLT.

Before operation	Y=14.14+0.07X R=0.359 (p<0.01)
Day 1	Y= 21.24+0.05X R=0.201 (p<0.05)
Day 3	Y=33.38-0.10X R=-0.331 (p<0.01)
Day 7	Y=18.68+0.08X R=0.253 (p<0.029)
Day 14	Y=19.42+0.11X R=0.566 (p<0.001)

X- Platelet count; Y- sGPVI.

Table 3: Relationship between the platelet count and sGPVI levels.

Thrombopoietin (TPO)

Ichikawa et al. [40] described out the role of TPO, which is catabolized by platelets within the spleen: the serum TPO levels after splenectomy peaked on POD3–5 and were then significantly reduced, which caused transient thrombocytosis on POD14. TPO, which is produced at a constant rate mainly in the normal hepatocytes [41], is known as the primary platelet regulator [42], and the steady-state amount of TPO is regulated by the thrombopoietin receptor, which is present on platelets [43]. In patients with a normal liver function, when the platelet counts significantly decrease under circumstances such as massive bleeding, there is a significant increase in the TPO levels, resulting in the production of platelets by megakaryocytes.

Von Willebrand factor (VWF) and VWF propeptide (VWFpp)

Pre-pro VWF is synthesized in endothelial cells and megakaryocytes, the VWFpp is cleaved but remains stored together with mature VWF in alpha-granules (megakaryocytes) and Weibel-Palade bodies (endothelial cells). After the secretion of VWFpp and VWF into the plasma from endothelial cells (after induction by physiological or pathological stimuli), VWFpp dissociates from VWF [44]. VWF mediates the adhesion of platelets to sites of vascular damage by binding to specific platelet membrane glycoproteins.

Elevated levels of VWF and VWFpp levels have been reported in cases of thrombotic thrombocytopenic purpura (TTP) [45] and DIC [46].

Disintegrin-like and metalloproteinase with thrombospondin type-1 motifs member 13 (ADAMTS13)

ADAMTS13 which is almost entirely produced by stellate cells in the hepatic sinusoid, specifically cleaves multimeric VWF [47,48]. In vascular endothelial cells, if plasma ADAMTS13 activity decreases, the number of unusually large VWF multimers (UL-VWFMs) significantly increases. Since UL-VWFMs show strong platelet aggregation activity, an increase in the level of UL-VWFMs leads to platelet clumping and/or thrombus formation [49]. Markedly decreased ADAMTS13 levels have been reported in cases of TTP [50].

Mechanism of Thrombocytopenia in LDLT

Thrombocytopenia is a common complication in liver diseases such as LDLT and occurs due to various causes, including bone marrow hematopoiesis failure due to the decreased production of TPO in the injured liver, increased platelet destruction with splenomegaly, the activation and consumption of platelets due to thrombosis, such as in cases of DIC [51], TMA [13], and venous thromboembolism (VTE) [52].

Platelet production

The TPO levels on POD14 were significantly higher in the LP group than in the HP group, while those on POD28 in the LP group were significantly decreased from those on POD14, being instead similar to those in the HP group despite the low platelet levels. This suggested that the constant production of TPO in the hepatocytes was preserved in the LP group on POD14, while on POD28 its production was significantly impaired, suggesting graft dysfunction. Although the reasons why the preoperative TPO levels were significantly higher in the LP group than in the HP group remained unclear, the low preoperative platelet counts in the LP group may be associated with the high TPO levels [27].

Increase in platelet destruction with splenomegaly

Thirty-eight (23.9%) of 159 adult patients who underwent LDLT were reported to have splenomegaly at 6 months after LDLT [53]. The spleen volume and the platelet levels at one month after LDLT may predict persistent splenomegaly at six months after LDLT. The predictive factors for hypersplenism at six months after LDLT may be the platelet levels at one week and at one month after LDLT. In a study to investigate the differences in the portal hemodynamics between DDLT and LDLT, although the portal venous pressure decreased after graft implantation, it was higher in LDLT patients with a smaller graft size than in DDLT patients [54].

Activation and consumption of platelets due to thrombosis

TMA: TMA is an infrequent but severe life-threatening disorder in solid organ transplant recipients. A small number of studies on TMA in LDLT recipients have been reported [13,14]. Decreased ADAMTS13 after LDLT might be associated with prolonged thrombocytopenia [55]. It has been reported that low ADAMTS13 activity may result from its low production or from increased consumption in the injured liver. In liver cirrhosis patients, the production of ADAMTS13 in hepatic stellate cells was reported to be decreased [56]. The behaviors

of ADAMTS13, VWF, and VWFpp have previously been reported in LDLT patients with TMA [13,53].

DIC: Decreased ADAMTS13 and elevated VWFpp have been reported in patients with DIC [57] and TMA [13], suggesting that ADAMTS13 is also consumed through the continuing cleavage of VWF or from the low production of ADAMTS13 in DIC patients. Although DIC and TMA are different diseases, they display similar hemostatic abnormalities to patients with LDLT. It is considered that local DIC may occur in cases of ABO incompatible LDLT [58].

VTE: Forty-eight (17%) of the 282 consecutive adult LDLTs recipients between April 2006 and December 2011 had pre-existing portal vein thrombosis (PVT) [59]. Although a fatal outcome occurred in a severe PVT patient who received an LDLT [60], excellent survival rates were reported in patients with PVT who underwent LDLT [59]. In another study, 68 (2.9%) of 2402 patients who underwent LDLT had PVT and those patients with PVT were found to have a worse prognosis than those without PVT [61].

Medication

Antibiotics, immunosuppressive agents such as mycophenolate, tacrolimus, and cyclosporin after LDLT, heparin, and many drugs can cause thrombocytopenia. Although the mechanisms differ by drug, monitoring the platelet count is important in at-risk patients, and the suspected drugs should be decreased or stopped when adverse event occur.

Behavior of Biomarkers in LDLT

Markedly decreased platelet counts and elevated sGPVI levels were observed, with the lowest platelet counts and the highest sGPVI levels seen on POD3. The sGPVI levels were positively correlated with the platelet counts before LDLT and negatively correlated with those on POD3, suggesting that the activation of platelets might be the highest on POD3. The ADAMTS13 levels in the patients with LDLT were the lowest on POD1, but the peaks differed between survivors and non-survivors [13,27,55]. The VWFpp levels were markedly elevated on POD7, but the peaks also differed between survivors and non-survivors [13,27,55]. The VWFpp and ADAMTS13 levels were considered to reflect vascular endothelial cell injury or liver graft dysfunction. The differences in hemostatic markers such as antithrombin (AT) and prothrombin time (PT), between the survivors and non-survivors were significant after POD14, suggesting that the liver function may still have been stable at POD14. ADAMTS13, VWF, and VWFpp have previously been studied as biomarkers for complications and poor outcomes after LDLT [13,27,55]. The high incidence of complications in non-survivors suggested that several complications might have contributed to deaths observed within 90 days after LDLT.

Conclusions

Severe thrombocytopenia after LDLT is associated with both graft loss and poor patient outcomes, thus underscoring the importance of monitoring the platelet count in patients after LDLT. Although the causes of thrombocytopenia vary, the mechanism should be clarified in each case. Therefore, the observation of biomarkers, such as sGPVI, TPO, VWF, VWFpp and ADAMTS13, is useful in the evaluation of the mechanisms of thrombocytopenia in patients who undergo LDLT.

Conflicts of Interest Statement

All of the authors declare no conflicts of interest.

Acknowledgments

This work was supported in part by a Grant-in-Aid from the Ministry of Health, Labour and Welfare of Japan for Blood Coagulation Abnormalities and the Ministry of Education, Culture, Sports, Science and Technology of Japan.

References

1. Nagasue N, Kohno H, Matsuo S, Yamanoi A, Uchida M, et al. (1992) Segmental (partial) liver transplantation from a living donor. *Transplant Proc* 24: 1958-1959.
2. Tanaka K, Uemoto S, Tokunaga Y, Fujita S, Sano K, et al. (1993) Surgical techniques and innovations in living related liver transplantation. *Ann Surg* 217: 82-91.
3. Makuuchi M, Kawasaki S, Noguchi T, Hashikura Y, Matsunami H, et al. (1993) Donor hepatectomy for living related partial liver transplantation. *Surgery* 113: 395-402.
4. Lee SG (2015) A complete treatment of adult living donor liver transplantation: A review of surgical technique and current challenges to expand indication of patients. *Am J Transplant* 15: 17-38.
5. Akamatsu N, Sugawara Y, Kokudo N (2014) Living-donor vs deceased-donor liver transplantation for patients with hepatocellular carcinoma. *World J Hepatol* 6: 626-31
6. Nagasue N, Kohno H, Matsuo S, Yamanoi A, Uchida M, et al. (1992) Segmental (partial) liver transplantation from a living donor. *Transplant Proc* 24: 1958-1959.
7. Egawa H, Oike F, Buhler L, Shapiro AM, Minamiguchi S, et al. (2004) Impact of recipient age on outcome of ABO-incompatible living-donor liver transplantation. *Transplantation* 77: 403-411.
8. Egawa H, Teramukai S, Haga H, Tanabe M, Fukushima M, et al. (2008) Present status of ABO-incompatible living donor liver transplantation in Japan. *Hepatology* 47: 143-152.
9. Farmer DG, Venick RS, McDiarmid SV, Ghobrial RM, Gordon SA, et al. (2007) Predictors of outcomes after pediatric liver transplantation: An analysis of more than 800 cases performed at single institution. *J Am Coll Surg* 204: 904-916.
10. Itoh S, Ikegami T, Yoshizumi T, Wang H, Takeishi K, et al. (2015) Long-term Outcome of Living-donor Liver Transplantation for Combined Hepatocellular-cholangiocarcinoma. *Anticancer Res* 35: 2475-2476.
11. McDiarmid SV, Anand R, Martz K, Millis MJ, Mazariegos G, et al. (2011) A multivariate analysis of pre-, peri-, and post-transplant factors affecting outcome after pediatric liver transplantation. *Ann Surg* 254: 145-154.
12. Uchiyama H, Kayashima H, Matono R, Shirabe K, Yoshizumi T, et al. (2012) Relevance of HLA compatibility in living donor liver transplantation: the double-edged sword associated with the patient outcome. *Clin Transplant* 26: E522-E529.
13. Takahashi N, Wada H, Usui M, Kobayashi T, Habe-Ito N, et al. (2013) Behavior of ADAMTS13 and Von Willebrand factor levels in patients after living donor liver transplantation. *Thromb Res* 131: 225-229.
14. Shindoh J, Sugawara Y, Akamatsu N, Kaneko J, Tamura S, et al. (2012) Thrombotic microangiopathy after living-donor liver transplantation. *Am J Transplant* 12:728-736.
15. Wada H, Matsumoto T, Yamashita Y, Hatada T (2014) Disseminated Intravascular Coagulation: Testing and Diagnosis. *Clin Chim Acta* 436C: 130-134.
16. Matsuo R, Ohkohchi N, Murata S, Ikeda O, Nakano Y, et al. (2008) Platelets strongly induce hepatocyte proliferation with IGF-1 and HGF in vitro. *J Surg Res* 145: 279-286.

17. Gerard D, Carlson ER, Gotcher JE, Jacobs M. (2006) Effects of platelet-rich plasma on the healing of autologous bone grafted mandibular defects in dogs. *J Oral Maxillofac Surg* 64: 443-451.
18. Nowatari T, Murata S, Fukunaga K, Ohkohchi N (2014) Role of platelets in chronic liver disease and acute liver injury. *Hepatol Res* 44: 165-172.
19. Matsuo R, Nakano Y, Ohkohchi N (2011) Platelet administration via the portal vein promotes liver regeneration in rats after 70% hepatectomy. *Ann Surg* 253: 759-763.
20. Kawasaki T, Murata S, Takahashi K, Nozaki R, Ohshiro Y, et al. (2010) Activation of human liver sinusoidal endothelial cell by human platelets induces hepatocyte proliferation. *J Hepatol* 53: 648-654.
21. Lang PA, Contaldo C, Georgiev P, El-Badry AM, Recher M, et al. (2008) Aggravation of viral hepatitis by platelet-derived serotonin. *Nat Med* 14: 756-761.
22. Kasahara M, Umeshita K, Inomata Y, Uemoto S (2013) Japanese Liver Transplantation Society: Long-term outcomes of pediatric living donor liver transplantation in Japan: an analysis of more than 2200 cases listed in the registry of the Japanese Liver Transplantation Society. *Am J Transplant* 13: 1830-1839.
23. Yamashiki N, Sugawara Y, Tamura S, Nakayama N, Oketani M, et al. (2012) Outcomes after living donor liver transplantation for acute liver failure in Japan: results of a nationwide survey. *Liver Transpl* 18: 1069-1077.
24. Tanemura A, Mizuno S, Wada H, Yamada T, Nobori T, (2012) Donor Age Affects Liver Regeneration during Early Period in the Graft Liver and Late Period in the Remnant Liver after Living Donor Liver Transplantation. *World J Surgery* 36: 1102-1111.
25. Chatzipetrou MA, Tsaroucha AK, Weppler D, Pappas PA, Kenyon NS, et al. (1999) Thrombocytopenia after liver transplantation. *Transplantation* 67: 702-706.
26. Chang FY, Singh N, Gayowski T, Wagener MM, Mietzner SM, et al. (2000) Thrombocytopenia in liver transplant recipients: predictors, impact on fungal infections, and role of endogenous thrombopoietin. *Transplantation* 69: 70-75.
27. Nobuoka Y, Wada H, Mizuno S, Kishiwada M, Usui M, et al. (2014) Prolonged thrombocytopenia after living donor liver transplantation is a strong prognostic predictor irrespective of splenectomy: the significance of ADAMTS13 and graft function. *Int J Hematol* 99: 418-428.
28. Takahashi K, Nagai S, Putchakayala KG, Safwan M, Li AY, et al. (2017) Prognostic impact of postoperative low platelet count after liver transplantation. *Clin Transplant*. (in press).
29. Buss DH, Cashell AW, O'Connor ML, Richards F (1994) Occurrence, etiology, and clinical significance of extreme thrombocytosis: a study of 280 cases. *Am J Med* 96: 247-253.
30. Kishi Y, Sugawara Y, Akamatsu N, Kaneko J, Tamura S, et al. (2005) Splenectomy and preemptive interferon therapy for hepatitis C patients after living- donor liver transplantation. *Clin Transpl* 19: 769-722.
31. Marubashi S, Dono K, Miyamoto A, Takeda Y, Nagano H, et al. (2007) Impact of graft size on postoperative thrombocytopenia in living donor liver transplant. *Arch Surg* 142:1054-1058.
32. Yoshizumi T, Taketomi A, Soejima Y, Ikegami T, Uchiyama H, et al. (2008) The beneficial role of simultaneous splenectomy in living donor liver transplantation in patients with small-for-size graft. *Transpl Int* 21: 833-842.
33. Leitinger B (2011) Transmembrane collagen receptors. *Annu Rev Cell Dev Biol* 27: 265-290.
34. Gardiner EE, Arthur JF, Kahn ML, Berndt MC, Andrews RK (2004) Regulation of platelet membrane levels of glycoprotein VI by a platelet-derived metalloproteinase. *Blood* 104: 3611-3617.
35. Gardiner EE, Karunakaran D, Shen Y, Arthur JF, Andrews RK, et al. (2007) Controlled shedding of platelet glycoprotein (GP)VI and GPIb-IX-V by ADAM family metalloproteinases. *J Thromb Haemost* 5: 1530-1537.
36. Al-Tamimi M, Gardiner EE, Thom JY, Shen Y, Cooper MN, et al. (2011) Soluble glycoprotein VI is raised in the plasma of patients with acute ischemic stroke. *Stroke* 42: 498-500.
37. Al-Tamimi M, Grigoriadis G, Tran H, Paul E, Servadei P, et al. (2011) Coagulation-induced shedding of platelet glycoprotein VI mediated by factor Xa. *Blood* 117: 3912-3920.
38. Aota T, Naitoh K, Wada H, Yamashita Y, Miyamoto N, et al. (2014) Elevated soluble platelet glycoprotein VI is a useful marker for DVT in postoperative patients treated with edoxaban. *Int J Hematol* 100: 450-456.
39. Yamashita Y, Naitoh K, Wada H, Ikejiri M, Mastumoto T, et al. (2014) Elevated plasma levels of soluble platelet glycoprotein VI (GPVI) in patients with thrombotic microangiopathy. *Thromb Res* 133: 440-444.
40. Ichikawa N, Kitano K, Shimodaira S, Ishida F, Ito T, et al. (1998) Changes in serum thrombopoietin levels after splenectomy. *Acta Haematol* 100: 137-141.
41. Nomura S, Ogami K, Kawamura K, Tsukamoto I, Kudo Y, et al. (1997) Cellular localization of thrombopoietin mRNA in the liver by in situ hybridization. *Exp Hematol* 25:565.
42. Kaushansky K (1995) Thrombopoietin: the primary regulator of megakaryocyte and platelet production. *Thromb Haemost* 74: 521-525.
43. Kaushansky K (2005) The molecular mechanisms that control thrombopoiesis. *J Clin Invest* 115: 3339-3347.
44. Federici AB (2006) VWF propeptide: a useful marker in VWD. *Blood* 108: 3229-3230.
45. Ito-Habe N, Wada H, Matsumoto T, Ohishi K, Toyoda H, et al. (2011) Elevated Von Willebrand factor propeptide for the diagnosis of thrombotic microangiopathy and for predicting a poor outcome. *Int J Hematol* 93: 47-52.
46. Habe K, Wada H, Ito-Habe N, Hatada T, Matsumoto T, et al. (2012) Plasma ADAMTS13, von Willebrand Factor (VWF) and VWF Propeptide Profiles in Patients with DIC and related Diseases. *Thromb Res* 129: 598-602.
47. Soejima K, Mimura N, Hirashima M, Maeda H, Hamamoto T, et al. (2001) A novel human metalloprotease synthesized in the liver and secreted into the blood: possibly, the von Willebrand factor-cleaving protease? *J Biochem* 130: 475-480.
48. Levy GG, Nichols WC, Lian EC, Foroud T, McClintick JN, et al. (2001) Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. *Nature* 413: 488-494.
49. Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle PA, et al. (1998) von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. *New Engl J Med* 339: 1578-1584.
50. Fujimura Y, Matsumoto M, Kokame K, Isonishi A, Soejima K, et al. (2009) Pregnancy-induced thrombocytopenia and TTP, and the risk of fetal death, in Upshaw-Schulman syndrome: a series of 15 pregnancies in 9 genotyped patients. *Br J Haematol* 144: 742-745.
51. Wada H, Thachil J, Di Nisio M, Mathew P, Kurosawa S, et al. (2013) The Scientific Standardization Committee on DIC of the International Society on Thrombosis Haemostasis: Guidance for diagnosis and treatment of DIC from harmonization of the recommendations from three guidelines. *J Thromb Haemost* 11: 761-767.
52. Annamalai A, Kim I, Sundaram V, Klein A (2014) Incidence and risk factors of deep vein thrombosis after liver transplantation. *Transplant Proc* 46: 3564-3569.
53. Chen TY, Chen CL, Huang TL, Tsang LL, Ou HY, et al. (2012) Predictive factors for persistent splenomegaly and hypersplenism after adult living donor liver transplantation. *Transplant Proc* 44: 752-754.
54. Jiang SM, Zhang QS, Zhou GW, Huang SF, Lu HM, et al. (2010) Differences in portal hemodynamics between whole liver transplantation and living donor liver transplantation. *Liver Transpl* 16: 1236-1241.
55. Kobayashi T, Wada H, Usui M, Sakurai H, Matsumoto T, et al. (2009) Decreased ADAMTS13 levels in patients after living donor liver transplantation. *Thromb Res* 124: 541-545.

-
56. Uemura M, Fujimura Y, Matsumoto M, Ishizashi H, Kato S, et al. (2008) Comprehensive analysis of ADAMTS13 in patients with liver cirrhosis. *Thromb Haemost* 99: 1019-1029.
 57. Hyun J, Kim HK, Kim JE, Lim MG, Jung JS, et al. (2009) Correlation between plasma activity of ADAMTS-13 and coagulopathy, and prognosis in disseminated intravascular coagulation. *Thromb Res* 124: 75-79.
 58. Kozaki K, Egawa H, Ueda M, Oike F, Yoshizawa A, et al. (2006) The role of apheresis therapy for ABO incompatible living donor liver transplantation: the Kyoto University experience. *Ther Apher Dial* 10: 441-448.
 59. Mori A, Iida T, Iwasaki J, Ogawa K, Fujimoto Y, et al. (2015) Portal vein reconstruction in adult living donor liver transplantation for patients with portal vein thrombosis in single center experience. *J Hepatobiliary Pancreat Sci* 22: 467-474.
 60. Mizuno S, Wada H, Hamada T, Nobuoka Y, Tabata M, et al. (2011) Lethal hepatic infarction following plasma exchange in living donor liver transplant patients. *Transpl Int* 24: e57-58.
 61. Saidi RF, Jabbour N, Li Y, Shah SA (2014) Outcomes of patients with portal vein thrombosis undergoing live donor liver transplantation. *Int J Organ Transplant Med* 5: 43-49.